Skip to main content
CRS 2026 Annual Meeting & Exposition Main banner

Nanomedicine and Nanoscale Delivery (Focus Group – NND)

PEGylated Liposomes as a Delivery Strategy to Enhance Rapamycin Anti-tumour Activity in Vascular Sarcoma

Lucy Wang, MPharm, RPh – Post-Doc, Pharmaceutical Sciences, University of Toronto; Linyu Fan, MSc – Lab Tech, University of Toronto; Albiruni Razak, MB BCh, BM BCh – Clinician Investigator, Princess Margaret Cancer Centre, University of Toronto,; Christine Allen, PhD – Professor, Pharmaceutical Sciences, Chemical Engineering and Applied Chemistry, University of Toronto

    Poster Presenter(s)

  • Zilu Chen

    PhD Student
    University of Toronto
    Toronto, Ontario, Canada

Introduction:

Epithelioid hemangioendothelioma (EHE) is a rare vascular sarcoma where patients with advanced/progressive disease face poor outcomes with no approved standard therapies.1 Rapamycin is an mTOR inhibitor with clinical activity against EHE but is limited by poor bioavailability and dose-limiting toxicity.2,3 Aimed at addressing these shortcomings, we present the development and in vivo evaluation of two liposomal formulations of rapamycin. In addition, by contrasting two drug loading techniques, we elucidate the impact of liposomal composition on in vivo efficacy in a relevant EHE tumour model.

Learning Objectives:

  • Recognize that rapamycin can be formulated into liposomes using remote loading strategies.
  • Compare how loading approaches influence rapamycin retention, release, and in vivo efficacy in liposomes.